Oxford University Innovation

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Retrieved on: 
星期三, 三月 20, 2024
MERS, Patient, Ethics, Epidemic, NUC, Group 3, Clinical trial, Liver, Depreciation, Vaccine, Hepatitis, PD-1, Research, Coalition, Arbutus, Hepatology, Coeliac disease, Nivolumab, Safety, Immune system, CHB, Prostate cancer, CEPI, AASLD, University, Șaeș, Cancer, HBV, Conference, AstraZeneca, Autoimmunity, Infection, Human papillomavirus infection, Oxford University Innovation, SNAP, HPV, APOLLO, Pharmaceutical industry

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Key Points: 
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • We presented the final data in June 2023 at the European Association for the Study of the Liver Congress 2023 – The International Liver CongressTM.
  • We presented this data during an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
  • In November 2023, we announced the company’s renaming as Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.

Liabilities, Damages and other Contentious Issues in International Commercial Agreements Training Course - ResearchAndMarkets.com

Retrieved on: 
星期五, 十月 27, 2023
Training, Education, Tim Thorogood, Trade, SME, London, BP, University of Oxford, International business, Breaking news, ADR, OBE, London Stock Exchange, Publication, Research, HM, BA, Oxford Institute of Legal Practice, Business, University, Motorola, Queen, Oxford University Innovation, KPMG, Lawyer, FRSA, Audit committee, Practice of law, Management

He was formerly a partner and Head of Commercial Law at KPMG Legal.

Key Points: 
  • He was formerly a partner and Head of Commercial Law at KPMG Legal.
  • Arun is cited and ranked in Chambers Guide of the World's Leading Lawyers.
  • He concentrates on international investment, joint ventures, licensing of technology, research and development, M&A, energy, outsourcing and corporate governance in developed and emerging markets.
  • He was appointed an OBE by HM the Queen in January 1999 for services to international trade, investment and intercultural management.

Infleqtion Names Dr. Marco Palumbo as Director of Business Development in the United Kingdom

Retrieved on: 
星期一, 十月 2, 2023
Business development, University of Salento, Innovate UK, University, Oxford, GNSS, UK National Quantum Technologies Programme, Durham, Government, Business, Satellite navigation, University of Surrey, ORCA (computer system), Machine learning, Engineering, Algorithm, Innovation, United Kingdom, Growth, Optimal design, Principal, Quantum, Oxford University Innovation, News, Microscope

OXFORD, England, Oct. 2, 2023 /PRNewswire/ -- Infleqtion, the world's quantum information company, today announced the appointment of Dr. Marco Palumbo to Director of Business Development, UK. Dr. Palumbo joins Infleqtion from Innovate UK, a non-departmental funding delivery agency of the British Government, where he served as Innovation Lead in the Quantum Technologies Challenge team, a unit responsible for more than £200m of investment in the quantum industry in the United Kingdom (UK) to date.

Key Points: 
  • OXFORD, England, Oct. 2, 2023 /PRNewswire/ -- Infleqtion , the world's quantum information company, today announced the appointment of Dr. Marco Palumbo to Director of Business Development, UK.
  • He will also develop and launch the next evolution of Infleqtion's growth strategy and foster relationships with potential customers across both public and private industries.
  • "I'm proud to welcome Dr. Marco Palumbo as the Director of Business Development at Infleqtion UK," said Scott Faris, CEO of Infleqtion.
  • "This is a time of rapid growth and development for both Infleqtion and the broader quantum industry," said Dr. Marco Palumbo, Director of Business Development, Infleqtion UK.

Gain Invaluable Insights from an International Legal Specialist: Liabilities, Damages and other Contentious Issues in International Commercial Agreements Training Course

Retrieved on: 
星期一, 九月 4, 2023
University of Oxford, University, ADR, London Stock Exchange, Queen, SME, Business, OBE, Lawyer, Breaking news, Research, Audit committee, Motorola, HM, BP, Publication, London, Tim Thorogood, Oxford University Innovation, Trade, International business, KPMG, FRSA, BA, Oxford Institute of Legal Practice, Practice of law, Management

He was formerly a partner and Head of Commercial Law at KPMG Legal.

Key Points: 
  • He was formerly a partner and Head of Commercial Law at KPMG Legal.
  • Arun is cited and ranked in Chambers Guide of the World's Leading Lawyers.
  • He concentrates on international investment, joint ventures, licensing of technology, research and development, M&A, energy, outsourcing and corporate governance in developed and emerging markets.
  • He was appointed an OBE by HM the Queen in January 1999 for services to international trade, investment and intercultural management.

NIST publish the highly anticipated draft standards for Quantum-Safe cryptography, supported by PQShield

Retrieved on: 
星期四, 八月 24, 2023
CRYSTALS, Max Planck Institute for Security and Privacy, NIST, Institute of Mathematics, HCLTech, University of Oxford, PQC, Partnership, Lattice Semiconductor, OpenSSL, AMD, National Cybersecurity Center of Excellence, Internet Engineering Task Force, Research, GSMA, Computer, Security, C, Radboud University Nijmegen, World Economic Forum, Algorithm, Oxford University Innovation, FIPS, Tata Consultancy Services, Microchip Technology, Growth, British, ANSSI, Collins Aerospace, TLS termination proxy, Quantum, AWS, Max Planck Society, Software, Medical device, Microscope, Cryptocurrency, Defense, Mathematics, Privacy

Following this, the draft standards will likely become the global benchmark for quantum-resistant cybersecurity across the world in 2024.

Key Points: 
  • Following this, the draft standards will likely become the global benchmark for quantum-resistant cybersecurity across the world in 2024.
  • The rise of quantum computers has led to an urgent need for new cryptographic standards to safeguard global privacy and data.
  • Dr Ali El Kaafarani, PQShield's founder and CEO, says: The release of the draft standards marks a significant turning point for PQShield and the entire cryptographic community.
  • NIST's new draft standards provide this assurance and a framework that allows everyone to move forward.

NIST publish the highly anticipated draft standards for Quantum-Safe cryptography, supported by PQShield

Retrieved on: 
星期四, 八月 24, 2023
CRYSTALS, Max Planck Institute for Security and Privacy, NIST, Institute of Mathematics, HCLTech, University of Oxford, PQC, Partnership, Lattice Semiconductor, OpenSSL, AMD, National Cybersecurity Center of Excellence, Internet Engineering Task Force, Research, GSMA, Computer, Security, C, Radboud University Nijmegen, World Economic Forum, Algorithm, Oxford University Innovation, FIPS, Tata Consultancy Services, Microchip Technology, Growth, British, ANSSI, Collins Aerospace, TLS termination proxy, Quantum, AWS, Max Planck Society, Software, Medical device, Microscope, Cryptocurrency, Defense, Mathematics, Privacy

Following this, the draft standards will likely become the global benchmark for quantum-resistant cybersecurity across the world in 2024.

Key Points: 
  • Following this, the draft standards will likely become the global benchmark for quantum-resistant cybersecurity across the world in 2024.
  • The rise of quantum computers has led to an urgent need for new cryptographic standards to safeguard global privacy and data.
  • Dr Ali El Kaafarani, PQShield's founder and CEO, says: The release of the draft standards marks a significant turning point for PQShield and the entire cryptographic community.
  • NIST's new draft standards provide this assurance and a framework that allows everyone to move forward.

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
星期四, 八月 10, 2023
Infection, EASL, Interferon gamma, PSA, Prostate cancer, Clinical trial, American depositary receipt, Cancer, Woman, Research, Autoimmunity, AstraZeneca, Hepatitis B, Public expenditure, Arbutus, Retirement, Investigational New Drug, ELISpot, Data, Patient, Laboratory, Immune system, Non-carious cervical lesions, HPV, Depreciation, European Association for the Study of the Liver, Vaccitech, HBV, Oxford University Innovation, IND, Disease, Conference, Safety, OUI, Nivolumab, Vaccine, Pharmaceutical industry, Clothing, Liver, HBsAg

Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.

Key Points: 
  • Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.
  • The final dataset, including data on clearance of infection and cervical lesions at 12 months post-treatment, is expected in the second quarter of 2024.
  • Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023.
  • Research and development expenses: Research and development expenses were $13.5 million in the second quarter of 2023 compared to $9.8 million in the first quarter of 2023, showing increased spend due to phasing of clinical and pre-clinical trials.

Brainomix Expands its UK Headquarters with New Facilities in Oxford

Retrieved on: 
星期一, 五月 15, 2023
University, Stroke, Cancer, Element, OXFORD, Creativity, Pulmonary fibrosis, Growth, AI, Oxford University Innovation, Pharmaceutical industry

The Brainomix team has grown to more than 60 employees, having more than doubled in size in the last 18 months.

Key Points: 
  • The Brainomix team has grown to more than 60 employees, having more than doubled in size in the last 18 months.
  • ft. of offices at Seacourt Tower purpose designed by Crown Interiors provides capacity for further UK expansion.
  • In addition, Brainomix has expanded internationally, with a US-based team and office facilities in Chicago.
  • The location is ideal and attractive to employees and should help us to retain and attract talent."

Brainomix Expands its UK Headquarters with New Facilities in Oxford

Retrieved on: 
星期一, 五月 15, 2023
University, Stroke, Cancer, Element, OXFORD, Creativity, Pulmonary fibrosis, Growth, AI, Oxford University Innovation, Pharmaceutical industry

The Brainomix team has grown to more than 60 employees, having more than doubled in size in the last 18 months.

Key Points: 
  • The Brainomix team has grown to more than 60 employees, having more than doubled in size in the last 18 months.
  • ft. of offices at Seacourt Tower purpose designed by Crown Interiors provides capacity for further UK expansion.
  • In addition, Brainomix has expanded internationally, with a US-based team and office facilities in Chicago.
  • The location is ideal and attractive to employees and should help us to retain and attract talent."

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
星期五, 五月 12, 2023
Vaccine, Infection, Antigen, Prostate-specific antigen, EASL, PSA, Cancer, Woman, CHB, Hepatitis B, Research, Autoimmunity, AASLD, AstraZeneca, Șaeș, Public expenditure, Congress, Arbutus, HBsAg, Retirement, CD8, Patient, Data, Laboratory, Non-carious cervical lesions, HPV, Depreciation, Poster, European Association for the Study of the Liver, CD4, Vaccitech, IND, Oxford University Innovation, HBV, Conference, Hepatitis, Safety, OUI, Disease, Pharmaceutical industry, E5, Liver, E4, E7, E2, E6

In April 2023, our Chief Medical Officer, Dr. Meg Marshall, presented interim data from APOLLO at the 35th Annual IPVC.

Key Points: 
  • In April 2023, our Chief Medical Officer, Dr. Meg Marshall, presented interim data from APOLLO at the 35th Annual IPVC.
  • In April 2023, we announced the planned retirement of Chris Ellis, Chief Operating Officer, effective October 31, 2023.
  • Cash position: As of March 31, 2023, cash was $191.3 million, compared to $194.4 million as of December 31, 2022.
  • Revenues: Revenue were $0.5 million in the first quarter of 2023 compared to $15.0 million in the comparable period of the previous year.